Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective αvβ3 inhibitor: Design, synthesis, and optimization
作者:Srinivasan R. Nagarajan、Hwang-Fun Lu、Alan F. Gasiecki、Ish K. Khanna、Mihir D. Parikh、Bipinchandra N. Desai、Thomas E. Rogers、Michael Clare、Barbara B. Chen、Mark A. Russell、Jeffery L. Keene、Tiffany Duffin、V. Wayne Engleman、Mary B. Finn、Sandra K. Freeman、Jon A. Klover、G. Alan Nickols、Maureen A. Nickols、Kristen E. Shannon、Christina A. Steininger、William F. Westlin、Marisa M. Westlin、Melanie L. Williams
DOI:10.1016/j.bmc.2007.03.020
日期:2007.5
The integrin alpha(v)beta(3) is expressed in a number of cell types and is thought to play a major role in several pathological conditions. Various small molecules that inhibit the integrin have been shown to suppress tumor growth and retinal angiogenesis. The tripeptide Arg-Gly-Asp (RGD), a common binding motif in several ligands that bind to alpha(v)beta(3), has been depeptidized and optimized in our efforts toward discovering a small molecule inhibitor. We recently disclosed the synthesis and biological activity of several small molecules that did not contain any peptide bond and mimic the tripeptide RGD. The phenethyl group in one of the lead compounds was successfully replaced with a cyclopropyl moiety. The new lead compound was optimized for potency, selectivity, and for its ADME properties. We describe herein the discovery, synthesis, and optimization of cyclopropyl containing analogs that are potent and selective inhibitors of alpha(v)beta(3). (c) 2007 Elsevier Ltd. All rights reserved.
US6921767B2
申请人:——
公开号:US6921767B2
公开(公告)日:2005-07-26
Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
申请人:——
公开号:US20040092538A1
公开(公告)日:2004-05-13
The present invention relates to a class of compounds represented by the Formula I
1
or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr;
v
&bgr;
3
and/or &agr;
v
&bgr;
5
integrin.
本发明涉及一类由公式I代表的化合物
1
或其药用可接受的盐,包含公式I化合物的药物组合物,以及选择性地抑制或拮抗α
v
β
3
和/或α
v
β
5
整合素的方法。
Enantioselective fluorination of homoallylic alcohols enabled by the tuning of non-covalent interactions
作者:Jaime A. S. Coelho、Akira Matsumoto、Manuel Orlandi、Margaret J. Hilton、Matthew S. Sigman、F. Dean Toste
DOI:10.1039/c8sc02223b
日期:——
The study of the enantioselective fluorination of homoallylicalcohols via chiral anion phase transfer (CAPT) catalysis using an in situ generated directing group is described. Multivariate correlation analysis, including designer π-interaction derived parameters, revealed key structural features affecting the selectivity at the transition state (TS). Interpretation of the parameters found in the model